scholarly journals Clinical use of Anti-Müllerian Hormone to Monitor Resumption of Ovarian Activity following Removal of a 4.7 mg Deslorelin Implant in Queens.

2021 ◽  
Author(s):  
Lluis Ferré Dolcet ◽  
Silvia Ferro ◽  
Barbara Contiero ◽  
Christelle Fontaine ◽  
Tamara Badon ◽  
...  
Keyword(s):  
Ovarian Function ◽  
Implant Removal ◽  
Vaginal Smear ◽  
Blood Collection ◽  
Ovarian Activity ◽  
Clinical Use ◽  
The Third ◽  
A Value ◽  
Prolonged Duration ◽  
Pre Treatment

Abstract Objective: The use of deslorelin implantsto control reproduction in cats is increasing but because of its prolonged duration, cat breeders oftenrequest implant removal before the end of the treatment. Assaying Anti Mullerian Hormone (AMH) concentrations might be useful to predict time of resumption of ovarian activity in deslorelin-treated queens following implant removal. In queens a minimum of 3 weeks during increasing photoperiod after implant removal has been described for resumption of ovarian activity but no information about AMH concentrations were observed for determining ovarian activity.Animals: Sixteen queens in whichdeslorelinimplants were surgically removed after3, 6 or 9 months (n= 6, 4 and 6 queens, respectively) were used in this study. Procedures: A general and reproductive health check with a GnRH stimulation test were performed before the treatment.After implant removal queens were checked every 1-2 weeks withreproductive ultrasonography, a vaginal smear and blood collection to assay AMHconcentrations. Results: AMH concentrations decreased significantly during treatment to < 2.5+0.6 ng/ml (p<0.05) and reached a nadir at 1.9+0.9 (p<0.05) one-week post-removal.Following implant removal AMH concentrations started to rise reaching a value of 4.3+1.2 ng/ml on the third week and were not different from pre-treatment levels on week 6 post-removal (5.8 ng/ml +0.9, p>0.05).AMH values did not differ depending on duration of deslorelin treatment but were lower in adult queens (p<0.05).Clinical relevance: AMH assay can be a useful tool to follow resumption of feline ovarian function following a deslorelin treatment.

scholarly journals Interval between Removal of a 4.7 mg Deslorelin Implant after a 3-, 6-, and 9-Month Treatment and Restoration of Testicular Function in Tomcats

Animals ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1559 ◽  
Author(s):  
Lluis Ferré-Dolcet ◽  
Lisa Carniello ◽  
Silvia Ferro ◽  
Andrea Cattai ◽  
Stefano Romagnoli ◽  
...  
Keyword(s):  
Reproductive Function ◽  
Serum Testosterone ◽  
Implant Removal ◽  
Blood Collection ◽  
Testicular Function ◽  
Clinical Exam ◽  
Testosterone Secretion ◽  
Prolonged Duration

Deslorelin implants have been used to produce a reversible sterilization in several species. In cats, the prolonged duration (12–15 months in tomcats and 18–22 months in queen) is often too much for cat breeders who request early implant removal. The interval between implant removal and resumption of reproductive function in cats has never been investigated. Eighteen tomcats received a 4.7 mg deslorelin implant placed in the periumbilical area and surgically removed during all seasons of the year after 3, 6, or 9 months (n = 6, 6, and 6 cats, respectively). Following implant removal, all cats received a clinical exam every two weeks, including testicular ultrasonographic measurement, observation of penile spikes, and blood collection for serum testosterone assay. Restoration of serum testosterone secretion occurred after 23 ± 6, 23 ± 6, and 22 ± 7 days in the 3-, 6-, and 9-month groups, respectively. Restoration of testicular function was confirmed by histology in 13/15 cats undergoing orchiectomy at the end of the study while the owners of the remaining two cats opted to maintain their animals intact. Removal of a 4.7 mg deslorelin implant after 3, 6, or 9 months is followed by resumption of serum testosterone secretion after about 3 weeks independent of age or season.

EFFECT OF ZINK TABLETS INTERVENTION IN ZINC DEFICIENCY OF TRIMESTER III PREGNANT WOMEN TOWARD WEIGHT AND BODY LENGTH OF NEWBORN

2021 ◽  
Vol 10 (2) ◽  
pp. 304-312
Author(s):  
Nurfadillah S ◽  
Wardihan Sinrang ◽  
Suryani As'ad ◽  
Muh. Nasrum Massi ◽  
Mardiana Ahmad ◽  
...  
Keyword(s):  
Birth Weight ◽  
Pregnant Women ◽  
Zinc Deficiency ◽  
Birth Length ◽  
World Health ◽  
Third Trimester ◽  
Average Value ◽  
The Third ◽  
A Value ◽  
Zinc Levels

Background: According to 2018 World Health Organization (WHO) data globally, an estimated 17.3% of the population has inadequate zinc intake, with estimates ranging from 5.7% in Oceania to 7.6% in Europe, 9.6% in America and the Caribbean, highest in Africa (23.9%) and Asia (19.6%). Zinc is important for the function of a number of enzymes and growth hormones during pregnancy. In pregnant women, the relative zinc concentration decreases up to 35% due to the influence of hormonal changes and the transport of nutrients from mother to baby. Objectives: The purpose of this study was to identify the effect of giving zinc tablets to pregnant women with zinc deficiency in the third trimester on body weight and length of babies born at the Makassar City Health Center. Methods: This type of research is True Experimental with a pretest-posttest design with a control group. The sample in this study was 62 samples of third trimester pregnant women, and the sampling technique used was purposive sampling. Measurement of zinc levels in third trimester pregnant women using the Elisa reader kit at the Research Laboratory of the Hasanuddin University Teaching Hospital. The research instruments were in the form of a research explanation sheet, respondent's consent sheet, respondent's checklist sheet, and the mother's zinc tablet consumption control sheet for 14 days. Results: Judging from the average value of newborns in pregnant women who did not have zinc deficiency, the average value of birth weight in pregnant women with zinc deficiency was 15.70 g/dL and 18.95 g/dL. zinc deficiency with a value (p < 0.05), while pregnant women with zinc deficiency have an average birth length of 10.00 g/dL and mothers who do not have a deficiency of 19.87 g/dL with a value (p < 0.05). So, it can be concluded that giving zinc tablets to pregnant women in the third trimester has an effect on Birth Weight (BBL) and Birth Length (PBL). Conclusion: Giving zinc tablets has an effect on increasing zinc levels in third trimester zinc deficiency pregnant women and increasing birth weight and length of the baby.  

Development of the Third Darrieus Blade of Sultan Wind Turbine for Low Wind Speed

2015 ◽  
Vol 758 ◽  
pp. 13-19 ◽  
Author(s):  
Erwin ◽  
Slamet Wiyono ◽  
Erny Listijorini ◽  
Rina Lusiani ◽  
Tresna P. Soemardi
Keyword(s):  
Wind Speed ◽  
Wind Turbine ◽  
Angle Of Attack ◽  
Optimum Combination ◽  
Chord Length ◽  
The Third ◽  
Low Wind Speed ◽  
A Value ◽  
Power Turbine ◽  
Naca 0012

Use of NACA 0012 at the Sultan Wind Turbine prototype provide value coefficient power turbine at wind speed 5.5 m / s by 0017 , wind speed 6.1 m / s at 0.015 , wind speed 7.7 m / s at 0.016 , wind speed 6.5 m / s for 0018 and wind speed 6.2 m / s by 0017 . Where the value of the highest efficiency obtained at a speed of 6.5 m / s at 0.018 . This result is not as expected to generate sufficient energy.The next development carried out investigations on some kind of airfoil, from investigations obtained by using Qblade software that NACA 6612 has a value of 1.78 CL at 15 degrees angle of attack is the largest of all the airfoil .In this research, NACA 6612 will be simulated with a variable chord length, angle of attack, and wind speed, of these three variables will be created which will map graphics 3d sliding value of the ratio of the 3 variables, this graph will give recommendations most optimum combination of variables to types are mapped wind speed throughout the year, to produce optimum power.Optimum combination of NACA 6612 with wind speed varied from 2-7 m/s is chord length 30 cm and angle of attack 7 degree.

scholarly journals Effects of Shaoyao-Gancao-Fuzi Decoction on the Pharmacokinetics of CYP3A4-Mediated Tofacitinib in Rats

2020 ◽  
Author(s):  
Li Lin ◽  
Yuan Wang ◽  
Sennan Shao ◽  
Wen Lin ◽  
Dan Huang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Oral Administration ◽  
Western Medicine ◽  
Control Group ◽  
Clinical Use ◽  
Pharmacokinetic Profiles ◽  
Pre Treatment ◽  
Cocktail Approach

Abstract Background: The combination of traditional Chinese medicine and western medicine is commonly accepted in clinics in China. Shaoyao-Gancao-Fuzi decoction (SGFD) has been extensively used to dispel wind, eliminate dampness and treat paralysis. Tofacitinib is approved for the treatment of rheumatoid arthritis. SGFD and tofacitinib could be used together for the treatment of rheumatoid arthritis.Methods: A cocktail approach was employed to assess the effects of SGFD on the activities of CYP450s. After pretreatment for 2 weeks with SGFD, a cocktail solution was given to rats 24 h after the last dose of saline or SGFD. Additionally, the pharmacokinetic profiles of oral administration of tofacitinib in rats, with or without SGFD pre-treatment were investigated.Results: The results showed that SGFD could induce the activity of CYP1A2 and inhibit the activity of CYP3A4. Furthermore, SGFD could significantly affect the pharmacokinetics of tofacitinib. Compared with control group, the AUC0-∞ of tofacitinib was increased from 13669.53 ± 4986.83 to 28706.69 ± 9563.13 ng/mL*h (p < 0.01), and the Cmax was increased from 8359.66 ± 1512.22 to 11332.51 ± 2791.90 ng/mL (p < 0.05).Conclusions: The system exposure of tofacitinib was increased by SGFD. The mechanism might be through inhibiting the activity of CYP3A4 and reducing the metabolism of tofacitinib in rats. The study will provide better guidance for the safe clinical use of SGFD and tofacitinib.

scholarly journals Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response

2021 ◽  
Vol 184 (2) ◽  
pp. 217-229
Author(s):  
Sabrina Chiloiro ◽  
Antonella Giampietro ◽  
Federica Mirra ◽  
Federico Donfrancesco ◽  
Tommaso Tartaglione ◽  
...  
Keyword(s):  
First Generation ◽  
Third Ventricle ◽  
Free Time ◽  
Second Line ◽  
Tumor Extension ◽  
The Third ◽  
Clinical Biomarkers ◽  
Predictors Of Response ◽  
Igf I ◽  
Pre Treatment

Background The treatment of acromegaly resistant to first-generation somatostatin receptor ligands (SRLs) is often difficult. Pegvisomant and Pasireotide LAR are mostly used in these subset of patients, as second line therapies. Choice of the type of second line therapies is difficult, since predictors of response are still unclear, impairing personalized therapy. We aimed to investigate predictors of response to Pegvisomant and Pasireotide LAR. Methods Seventy-four acromegaly patients entered this observational, cross-sectional and retrospective study if (i) resistant to high dose first-generation SRLs and (ii) treated with Pegvisomant and Pasireotide LAR for at least 12 consecutive months. Patients treated with radiotherapy in the previous 10 years were excluded. Results Fourty-one patients were treated with Pegvisomant and 33 with Pasireotide LAR. At the end of the study, acromegaly was controlled in 35 patients treated with Pegvisomant (85.4%) and in 23 treated with Pasireotide LAR (69.7%). In this cohort, a poor Pegvisomant response and a shorter progression free time were observed in cases with tumor extension to the third ventricle (P = 0.004, HR: 1.6, 95%CI: 1.2–4.6), with a Ki67-Li >4% (P = 0.004, HR: 3.49, 95%CI: 1.4–4.0) and with pre-treatment IGF-I >3.3×ULN (P=0.03, HR: 1.3, 95%CI: 1.1–6.0). A poor Pasireotide LAR response and a shorter progression free time were observed in cases with tumor extension to the third ventricle (P=0.025, HR: 1.6 95%CI: 1.4–3.4), pre-treatment IGF-I >2.3×ULN (P=0.049, HR: 2.4, 95%CI: 1.4–8.0), absent/low SST5 membranous expression (P=0.023 HR: 4.56 95%CI: 1.3–6.4) and in patients carried the d3-delated GHR isoform (P=0.005, HR: 11.37, 95%CI: 1.3–20.0). Conclusion Molecular and clinical biomarkers can be useful in predicting the responsiveness to Pegvisomant and Pasireotide LAR.

Seasonal differences in ovarian activity in cows

1984 ◽  
Vol 102 (2) ◽  
pp. 189-198 ◽  
Author(s):  
K. P. McNatty ◽  
N. Hudson ◽  
M. Gibb ◽  
K. M. Henderson ◽  
S. Lun ◽  
...  
Keyword(s):  
Granulosa Cells ◽  
Ovarian Function ◽  
Plasma Concentrations ◽  
Peak Frequency ◽  
Ovarian Activity ◽  
Corpora Lutea ◽  
Aromatase Activity ◽  
Plasma Prolactin ◽  
Seasonal Differences ◽  
Time Of Year

ABSTRACT The plasma concentrations of LH and prolactin and various parameters of ovarian function were examined in cows on known days of the oestrous cycle during May and June (autumn and winter) and during October (spring). Luteinizing hormone peak frequency and plasma prolactin concentrations were significantly higher in October than during the May–June period (LH, P<0·05; prolactin, P<0·01). The mean diameters of large healthy follicles (≥8 mm diameter) and the dominant oestrogen-secreting follicles were significantly larger (P<0·01 for both follicle types) and each follicle contained more granulosa cells (both P<0·01) in May–June than in October. The LH responsiveness of theca interna with respect to androstenedione production and the levels of aromatase activity in granulosa cells did not differ with time of year. The corpora lutea were heavier (P<0·05) and secreted more progesterone (P<0·01) in May–June than in October. It is concluded that seasonal differences in ovarian activity exist in cows and that these differences are probably the consequence of seasonal differences in gonadotrophin secretion. J. Endocr. (1984) 102, 189–198

The Physiology of Carbon Dioxide Transport in Insect Blood

1950 ◽  
Vol 27 (2) ◽  
pp. 158-174 ◽  
Author(s):  
L. LEVENBOOK
Keyword(s):  
Carbon Dioxide ◽  
Dissociation Constant ◽  
Temperature Coefficient ◽  
Carbonic Acid ◽  
Apparent Dissociation Constant ◽  
Carbon Dioxide Transport ◽  
High Co2 ◽  
The Third ◽  
A Value ◽  
Dissociation Curves

1. The pH of the blood of the third instar Gastrophilus larva is 6.64 at 38° C. with a pH-temperature coefficient of -0.007 Per 1° C. rise in temperature. 2. The total CO2 content of the blood varies from 40.6 to 131.4 vol. % with an average of 72.4 vol. %. The CO2 content of the tissues minus the cuticle is very close to, and follows the variations in, the CO2 content of the blood. 3. The CO2 tension in the blood is from 300 to 500 mm. Hg. From 30 to 50% of the CO2 is in solution, the rest in the form of bicarbonate. Carbamate formation does not occur in the blood. 4. The ‘apparent’ dissociation constant for carbonic acid, (pK'1), has a value of 6.08 (S.D. ±0.06) at 38° C. and 6.19 (s.d. ±0.13) at 16° C. 5. CO2 dissociation curves have been drawn for 38 and 16° C. The slope of the curves indicates that the whole of the CO2 is given off at zero CO2 tension, and that the blood is adapted for functioning at high CO2 tensions.

Max Weber’s ethics

2019 ◽  
Vol 16 (3) ◽  
pp. 305-322
Author(s):  
Richard Ned Lebow
Keyword(s):  
Foreign Policy ◽  
Policy Assessment ◽  
External Knowledge ◽  
The Third ◽  
A Value ◽  
To Come ◽  
Expected Outcomes

I offer a critique of Weber’s two ethics. The first layer is internal and concerned with their logics. The second layer considers the external knowledge necessary to apply them appropriately and argues that it is extremely difficult to come by. The third layer connects Weber’s ethics to his politics because the choice of either ethic in almost any context is a value choice. This is apparent in Weber’s application of these ethics to Germany foreign policy. He used his ethics in a rhetorical way to justify his values rather than using these values as a guide to policy assessment. This reversal is endemic to politics. One response might be to stipulate beforehand the kinds of policies that are unacceptable in democracies regardless of their expected outcomes.

scholarly journals Precision Betacarotene Supplementation Enhanced Ovarian Function and the LH Release Pattern in Yearling Crossbred Anestrous Goats

Animals ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 659
Author(s):  
Noé M. Lopez-Flores ◽  
César A. Meza-Herrera ◽  
Carlos Perez-Marin ◽  
Dominique Blache ◽  
Gerardo Arellano-Rodríguez ◽  
...  
Keyword(s):  
Ovarian Function ◽  
Body Condition Score ◽  
Area Under The Curve ◽  
Live Weight ◽  
Beta Carotene ◽  
Ovarian Activity ◽  
Release Pattern ◽  
Time Treatment ◽  
Condition Score ◽  
Lh Release

The possible out-of-season effect of beta-carotene supplementation on ovulation rate (OR), antral follicles (AFN), and total ovarian activity (TOA = OR + AFN) as related to the LH release pattern in yearling anestrous goats was evaluated. In late April, Alpine-Saanen-Nubian x Criollo goats (n = 22, 26 N) were randomly allotted to: (1) Beta-carotene (BETA; n = 10, orally supplemented with 50 mg/goat/d; 36.4 ± 1.07 kg live weight (LW), 3.5 ± 0.20 units, body condition score (BCS) or (2) Non-supplemented (CONT; n = 12, 35.2 ± 1.07 kg LW, 3.4 ± 0.2 units BCS). Upon estrus synchronization, an intensive blood sampling (6 h × 15 min) was accomplished in May for LH quantifications; response variables included (pulsatility-PULSE, time to first pulse-TTFP, amplitude-AMPL, nadir-NAD and area under the curve-AUC). Thereafter, an ultrasonography scanning was completed to assess OR and AFN. The Munro algorithm was used to quantify LH pulsatility; if significant effects of time, treatment or interaction were identified, data were compared across time. Neither LW nor BCS (p > 0.05) or even the LH (p > 0.05); PULSE (4.1 ± 0.9 pulses/6 h), NAD (0.47 ± 0.13 ng) and AUC (51.7 ± 18.6 units) differed between treatments. Nonetheless, OR (1.57 vs. 0.87 ± 0.18 units) and TOA (3.44 vs. 1.87 ± 0.45 units) escorted by a reduced TTFP (33 vs. 126 ± 31.9 min) and an increased AMPL (0.55 vs. 0.24 ± 0.9 ng), favored to the BETA supplemented group (p < 0.05), possibly through a GnRH-LH enhanced pathway and(or) a direct effect at ovarian level. Results are relevant to speed-up the out-of-season reproductive outcomes in goats while may embrace translational applications.

Sign in / Sign up

Export Citation Format

Share Document